A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of
an open label safety lead-in (Part A), followed by randomized, double-blind,
placebo-controlled treatment (Part B).